Matrix metalloproteases and lung disease.

O'connor, Clare M.; FitzGerald, M. X.

doi:10.1136/thx.49.6.602

Cited by 131 publications

(109 citation statements)

References 78 publications

Supporting

Mentioning

101

Contrasting

Unclassified

Order By: Relevance

“…The deposition of excessive collagen results from an imbalance in collagen turnover, and MMPs are the key enzymes involved in ECM degradation in physiological and pathological conditions. MMPs have also been implicated in a range of pulmonary diseases characterized by alterations in alveolar structure, including interstitial fibrosis, acute respiratory distress syndrome, chronic obstructive pulmonary disease, asthma, and lung cancer (O'Connor and FitzGerald 1994). During the host defense response, in which inflammatory cells are attracted to the lung to combat microorganisms and other irritants deposited in the airways, potent proteolytic enzymes, including MMPs, are produced and facilitate the clearance of foreign and noxious agents.…”

Section: Discussionmentioning

confidence: 99%

Blockade of the Wnt/.BETA.-Catenin Pathway Attenuates Bleomycin-Induced Pulmonary Fibrosis

Kim

Seo

et al. 2011

Tohoku J. Exp. Med.

114

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Blockade of the Wnt/.BETA.-Catenin Pathway Attenuates Bleomycin-Induced Pulmonary Fibrosis

Kim

Seo

et al. 2011

Tohoku J. Exp. Med.

114

View full text Add to dashboard Cite

“…Thus, the intake of beta-1,3/1,6-glucans may reduce inflammation in canine osteoarthritis and thereby reduce pain. TNFα also stimulates the production of matrix metalloproteinase-3 (MMP-3) by chondrocytes (O'Connor and Fitzgerald, 1994). MMP-3 is involved in the degradation of collagen molecules in the cartilage matrix.…”

Section: Discussionmentioning

confidence: 99%

Influence of Dietary Beta-1,3/1,6-Glucans on Clinical Signs of Canine Osteoarthritis in a Double-Blind, Placebo-Controlled Trial

Beynen¹

2010

American Journal of Animal and Veterinary Sciences

View full text Add to dashboard Cite

Problem statement: There are indications for a beneficial effect of beta-1,3/1,6-glucans on the clinical signs of dogs with osteoarthritis. Data from a controlled trial were necessary to prove or disprove the indications. Approach: A double-blind, placebo-controlled trial with privately owned dogs was carried out to assess the efficacy of a preparation of beta-1,3/1,6-glucans in the treatment of osteoarthritis. With the use of a questionnaire, the clinical signs were evaluated by the owners. For a period of 8 weeks, the test dogs daily received a complete dry food without or with 800 ppm beta-1,3/1,6-glucans. There were 23 dogs per experimental group. Results: When compared with the baseline values, the administration of beta-1,3/1,6-glucans significantly improved activity (vitality) and significantly reduced stiffness, lameness and pain. In the placebo group there only was a significant change in the clinical signs of stiffness. When the changes over time for the two groups were compared, there were no statistically significant differences, but the test group showed greater numerical improvement as to the scores for activity, stiffness, lameness and pain. Conclusion: Beta-1,3/1,6-glucans can be considered safe and it is suggested that a dose of 800 ppm in a dry food would be beneficial for dogs with osteoarthritis.

show abstract

“…EBSs are present in the promoters of many genes involved in cellular proliferation, differentiation, development, hemopoiesis, apoptosis, metastasis, tissue remodeling, and angiogenesis (21,22). Although several cytokines elicit MMP-9 and tenascin expression, TNF-␣ is particularly potent (23,24). TNF-␣ markedly upregulated MMP-9 production in human endothelial cells (25), fibroblasts (26), and leukemia cells (27) and was the most potent tenascin inducer in fibroblastic cells (28).…”

mentioning

confidence: 99%

Ets-1 Regulates TNF-α-Induced Matrix Metalloproteinase-9 and Tenascin Expression in Primary Bronchial Fibroblasts

Nakamura

Esnault

Maeda

et al. 2004

The Journal of Immunology

View full text Add to dashboard Cite

Increased subepithelial deposition of extracellular matrix proteins is a key feature in bronchial asthma. Matrix metalloproteinase-9 (MMP-9) is a proteolytic enzyme that degrades the extracellular matrix. Tenascin is an extracellular matrix glycoprotein that is abundant in thickened asthmatic subbasement membrane. The expression of MMP-9 and tenascin reflects disease activity in asthma and airway remodeling. The molecular mechanisms regulating the expression of these proteins remain unknown. Both MMP-9 and tenascin promoters contain an Ets binding site, suggesting control by Ets-1. Thus, we hypothesized that Ets-1 expression is increased in asthma and that it contributed to enhanced MMP-9 and tenascin expression. To test this hypothesis, we determined the expression of Ets-1 in bronchial biopsies obtained from asthmatic subjects and determined the expression of Ets-1, MMP-9, and tenascin by bronchial fibroblasts activated ex vivo. We observed that nuclear extracts from TNF-α-activated fibroblasts showed increased Ets-binding activity. In addition, TNF-α-activated fibroblasts had increased expression of Ets-1 mRNA and protein, which preceded an increase in MMP-9 and tenascin mRNA. Furthermore, treatment of fibroblasts with Ets-1 antisense oligonucleotides down-regulated TNF-α-induced Ets-1, MMP-9, and, to a lesser extent, tenascin protein expression or activity. Taken together, these data demonstrate that TNF-α increases MMP-9 and tenascin expression in bronchial fibroblasts via the transcription factor Ets-1, and suggest a role for Ets-1 in airway remodeling in asthma.

show abstract

Matrix metalloproteases and lung disease.

Cited by 131 publications

References 78 publications

Blockade of the Wnt/.BETA.-Catenin Pathway Attenuates Bleomycin-Induced Pulmonary Fibrosis

Blockade of the Wnt/.BETA.-Catenin Pathway Attenuates Bleomycin-Induced Pulmonary Fibrosis

Influence of Dietary Beta-1,3/1,6-Glucans on Clinical Signs of Canine Osteoarthritis in a Double-Blind, Placebo-Controlled Trial

Ets-1 Regulates TNF-α-Induced Matrix Metalloproteinase-9 and Tenascin Expression in Primary Bronchial Fibroblasts

Contact Info

Product

Resources

About